Norges Bank’s Celldex Therapeutics CLDX Stock Holding History

Norges Bank’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-92,900	Closed	-$2.5M	–	2097
2022 Q2	$2.5M	Buy	+92,900	New	+$2.7M	﹤0.01%	1873
2021 Q3	–	Sell	-32,200	Closed	-$1.08M	–	2283
2021 Q2	$1.08M	Buy	+32,200	New	+$884K	﹤0.01%	2107
2017 Q2	–	Sell	-23,507	Closed	-$1.27M	–	2134
2017 Q1	$1.27M	Hold	23,507	–	–	﹤0.01%	2030
2016 Q4	$1.25M	Hold	23,507	–	–	﹤0.01%	2012
2016 Q3	$1.36M	Sell	23,507 -5,000	-18%	-$311K	﹤0.01%	2012
2016 Q2	$1.88M	Hold	28,507	–	–	﹤0.01%	2006
2016 Q1	$1.62M	Sell	28,507 -11,367	-29%	-$1.28M	﹤0.01%	2013
2015 Q4	$9.38M	Sell	39,874 -4,601	-10%	-$1M	﹤0.01%	1627
2015 Q3	$7.03M	Hold	44,475	–	–	﹤0.01%	1749
2015 Q2	$16.8M	Buy	44,475 +13,037	+41%	+$5.18M	0.01%	1291
2015 Q1	$13.1M	Hold	31,438	–	–	0.01%	1485
2014 Q4	$8.61M	Sell	31,438 -3,665	-10%	-$911K	﹤0.01%	1711
2014 Q3	$6.82M	Sell	35,103 -52,731	-60%	-$11.5M	﹤0.01%	1789
2014 Q2	$21.5M	Buy	+87,834	New	+$19.8M	0.01%	1587

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Norges Bank's CLDX Position: Q3 2022 in Review

Norges Bank sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 92,900 shares — an estimated $2.5M sold.

Norges Bank first reported a position in CLDX in Q2 2014 and held it in 14 quarters. The position peaked at $21.5M in Q2 2014. 158 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

Norges Bank reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
Norges Bank sold 92,900 Celldex Therapeutics shares in Q3 2022, an estimated $2.5M.
Norges Bank first reported a position in Celldex Therapeutics in Q2 2014 and held it in 14 quarters.
Norges Bank's Celldex Therapeutics position peaked at $21.5M in Q2 2014.
158 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Norges Bank's 13F filing for Q3 2022, filed 14 Nov 2022.